Saturday, October 16, 2021
53 F
Fort Worth

AstraZeneca acquires ZS Pharma in $2.7 billion deal

🕐 1 min read

LONDON (AP) — Anglo-Swedish drug firm AstraZeneca has acquired U.S.-based biopharmaceutical company ZS Pharma in a deal worth $2.7 billion.

ZS Pharma was founded by Dr. Al Guillem and Dr. Jeff Keyser, both formerly with Adams Laboratories in Fort Worth. The company was a TECH Fort Worth client and also received an investment from the Texas Emerging Technology Fund.

The deal will give AstraZeneca access to ZS Pharma’s treatment for hyperkalemia, a condition of elevated potassium in the bloodstream that is associated with chronic kidney disease and chronic heart failure. The treatment, potassium-binding compound ZS-9, is under regulatory review by the U.S. Food and Drug Administration.

The deal values the San Mateo, California-based company at $90 a share.

ZS Pharma’s CEO Robert Alexander says the agreement will maximize the potential of ZS-9 and draw on AstraZeneca’s expertise in developing medicines for cardiovascular and metabolic diseases.

Like other big drugmakers, AstraZeneca is trying to build its product portfolio to combat competition from generic drugmakers as it loses exclusivity on top sellers. ZS Pharma had been in talks to be acquired by Actelion Ltd. of Switzerland.

Related Articles

Our Digital Sponsors

Latest Articles

Not ready to subscribe?

Try a few articles on us.

Enter your email address and we will give you access to three articles a month, to give us a try. You also get an opportunity to receive our newsletter with stories of the day.

Get our email updates

Stay up-to-date with the issues, companies and people that matter most to business in the Fort Worth.

  • Restaurants
  • Technology
  • and more!

FWBP Morning Brief

FWBP 5@5

Weekend Newsletter

  • Banking & Finance
  • Culture
  • Real Estate